Table 4.
Association of G1m status with change in DAS28 at 6 months of treatment with anti-TNF
| Unadjusted | Adjusted b | |||||||
|---|---|---|---|---|---|---|---|---|
| First replication | G1m genotype a | number | Baseline DAS28 | ΔDAS28 | Beta | P-value | Beta | P-value |
| All patients | G1m1,17+ | 228 | 6.4 ± 1.1 | 2.5 ± 1.3 | 0.03 | 0.52 | 0.07 | 0.13 |
| G1m1,17- | 176 | 6.6 ± 1.1 | 2.4 ± 1.3 | |||||
| INX | G1m1,17+ | 116 | 6.7 ± 0.9 | 2.5 ± 1.2 | 0.14 | 0.04 | 0.15 | 0.02 |
| G1m1,17- | 83 | 6.8 ± 1.1 | 2.2 ± 1.3 | |||||
| ADM | G1m1,17+ | 112 | 6.1 ± 1.1 | 2.4 ± 1.3 | −0.07 | 0.32 | −0.01 | 0.83 |
| G1m1,17- | 93 | 6.4 ± 1.0 | 2.8 ± 1.3 | |||||
| Second replication | ||||||||
| INX | G1m1,17+ | 203 | 6.2 ± 1.1 | 2.2 ± 1.5 | 0.11 | 0.03 | 0.08 | 0.08 |
| G1m1,17- | 159 | 6.1 ± 1.3 | 1.9 ± 1.5 | |||||
aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab.